GnRH Antagonist Pre-treatment for the Prevention of Asynchronous Follicular Growth
Status:
Recruiting
Trial end date:
2023-03-01
Target enrollment:
Participant gender:
Summary
In the study the investigators would like to examine the effect of GnRH antagonist
administration at the beginning of the follicular phase in patients presenting with high
baseline estradiol levels of 200 pmol/L or above with a leading follicle of 11-13 mm. In the
unit's practice, patients presenting for cycle initiation with a leading follicle > 10 in the
presence of E2 > 200 pmol/L (54 pg/ml) are deferred and receive a priming antagonist protocol
in their sequential cycle. The aim of this intervention is to suppress FSH levels at the
beginning of the cycle thus preventing estradiol secretion of the leading follicle. This may
contribute to better synchronization of the remaining antral follicles cohort and allow for a
better cycle outcome instead of cancellation or one-month postponement. As previous studies
using GnRH antagonist pre-treatment prior to GT initiation for synchronization purposes
demonstrated positive results (including different patient population) , no deleterious
effects are expected.